US Pharma MarketingOlympus pushes deeper into oncology with $270M BioProtect deal
Olympus pushes deeper into oncology with $270M BioProtect deal is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Olympus is pushing deeper into prostate cancer care with the acquisition of BioProtect, an Israeli company whose biodegradable balloon spacer has been used in more than 11,000 procedures worldwide.
Source: FierceBiotech